Dicerna Pharmaceuticals (DRNA) Reaches $8.44 52-Week High; Moduslink Global Solutions (MLNK) Shorts Down By 16.29%

November 15, 2017 - By Migdalia James

The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) hit a new 52-week high and has $9.20 target or 9.00% above today’s $8.44 share price. The 9 months bullish chart indicates low risk for the $175.96 million company. The 1-year high was reported on Nov, 15 by Barchart.com. If the $9.20 price target is reached, the company will be worth $15.84 million more. About 42,689 shares traded. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 5.22% since November 15, 2016 and is downtrending. It has underperformed by 21.92% the S&P500.

Moduslink Global Solutions Incorporated (NASDAQ:MLNK) had a decrease of 16.29% in short interest. MLNK’s SI was 456,300 shares in November as released by FINRA. Its down 16.29% from 545,100 shares previously. With 48,800 avg volume, 9 days are for Moduslink Global Solutions Incorporated (NASDAQ:MLNK)’s short sellers to cover MLNK’s short positions. The SI to Moduslink Global Solutions Incorporated’s float is 1.27%. About 15,779 shares traded. ModusLink Global Solutions, Inc. (NASDAQ:MLNK) has risen 13.77% since November 15, 2016 and is uptrending. It has underperformed by 2.93% the S&P500.

ModusLink Global Solutions, Inc. is a well-known provider of supply chain and logistics services through its subsidiaries, ModusLink Corporation and ModusLink PTS, Inc. The company has market cap of $96.67 million. The Firm provides services to companies in the consumer electronics, communications, computing, software, storage and retail industries. It currently has negative earnings. The Firm operates through four divisions: Americas, Asia, Europe and e-business.

Investors sentiment decreased to 0.78 in 2017 Q2. Its down 0.89, from 1.67 in 2017Q1. It dived, as 8 investors sold ModusLink Global Solutions, Inc. shares while 10 reduced holdings. 6 funds opened positions while 8 raised stakes. 31.37 million shares or 2.00% less from 32.01 million shares in 2017Q1 were reported. Northern Trust Corporation, a Illinois-based fund reported 139,228 shares. Guggenheim Ltd holds 11,267 shares. Tower Research Capital Ltd Com (Trc) holds 7,105 shares. Geode Capital Ltd owns 191,212 shares. Bollard Ltd Liability reported 23,160 shares. Credit Agricole S A has 0% invested in ModusLink Global Solutions, Inc. (NASDAQ:MLNK) for 25 shares. Credit Suisse Ag invested 0% of its portfolio in ModusLink Global Solutions, Inc. (NASDAQ:MLNK). Vanguard Grp Inc Inc accumulated 0% or 1.50M shares. State Street Corporation invested 0% in ModusLink Global Solutions, Inc. (NASDAQ:MLNK). Howe Rusling stated it has 123 shares. 6,072 are held by Lenox Wealth Management. Jbf Cap accumulated 10,000 shares. Grt Capital Prns Limited Liability Com holds 0.05% or 47,608 shares in its portfolio. Teton Advsrs Inc, a New York-based fund reported 1.64 million shares. Dimensional Fund Advsr Lp stated it has 1.79M shares or 0% of all its holdings.

Analysts await Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to report earnings on March, 29. They expect $-0.64 EPS, up 5.88% or $0.04 from last year’s $-0.68 per share. After $-0.92 actual EPS reported by Dicerna Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -30.43% EPS growth.

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid interference biopharmaceutical company. The company has market cap of $175.96 million. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It currently has negative earnings. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals has $30 highest and $3.50 lowest target. $9.88’s average target is 17.06% above currents $8.44 stock price. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, November 11 by Stifel Nicolaus. H.C. Wainwright initiated Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Monday, December 12 with “Buy” rating. The rating was maintained by Cowen & Co on Tuesday, July 18 with “Buy”. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has “Hold” rating given on Friday, August 11 by Chardan Capital Markets. The company was maintained on Thursday, June 30 by Chardan Capital Markets. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus on Thursday, June 30. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has “Buy” rating given on Monday, August 10 by Stifel Nicolaus. Stifel Nicolaus maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Thursday, November 2 with “Buy” rating. On Tuesday, September 8 the stock rating was initiated by Cowen & Co with “Outperform”. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 11.

Investors sentiment decreased to 0.55 in 2017 Q2. Its down 0.40, from 0.95 in 2017Q1. It dived, as 9 investors sold Dicerna Pharmaceuticals Inc shares while 11 reduced holdings. 4 funds opened positions while 7 raised stakes. 11.04 million shares or 3.09% more from 10.71 million shares in 2017Q1 were reported. Bancorporation Of New York Mellon holds 0% or 28,564 shares. Tfs Cap has 0.02% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Qs Investors Limited Liability Company invested in 0% or 1,071 shares. Morgan Stanley owns 0% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 1,246 shares. Moreover, Financial Bank Of America Corp De has 0% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 35 shares. Ecor1 Lc has 767,992 shares for 0.43% of their portfolio. Dimensional Fund Advisors Limited Partnership holds 0% or 32,024 shares in its portfolio. Moreover, Renaissance Tech Ltd Liability Company has 0% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 443,100 shares. Eventide Asset Mngmt Ltd Company holds 377,000 shares or 0.07% of its portfolio. Wells Fargo & Mn holds 0% or 140 shares in its portfolio. Geode Mngmt Ltd Co accumulated 82,690 shares. Barclays Pcl owns 78 shares for 0% of their portfolio. The Massachusetts-based Fmr Ltd Co has invested 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Jpmorgan Chase & Com has 3,370 shares for 0% of their portfolio. Federated Incorporated Pa invested in 541 shares or 0% of the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com